SCHEMBL2332679

SCHEMBL2332679

COC(=O)C1C2CCC(O2)C1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPM1B O75688 3/20 1.00
PTPN1 P18031 3/20 1.00
PPP1CC P36873 3/20 1.00
TFPI2 P48307 5/20 0.68
LMNA P02545 2/20 0.68
KDM4E B2RXH2 1/20 0.68
GMNN O75496 1/20 0.68
PMP22 Q01453 1/20 0.68
TP53 P04637 1/20 0.68
TSHR P16473 1/20 0.68
NFKB1 P19838 1/20 0.68
THPO P40225 1/20 0.68
PPP1CA P62136 2/20 0.50
PPP5C P53041 2/20 0.49
PPP2CA P67775 1/20 0.49
NPY4R P50391 1/20 0.49
GAA P10253 1/20 0.48
SLC6A4 P31645 1/20 0.48
SLC6A3 Q01959 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8758857 1.00 PPM1B (1.00) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL26613051 1.00 PPM1B (1.00) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL9460572 1.00 PPM1B (1.00) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL390763 1.00 PPM1B (1.00) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL15590874 1.00 PPM1B (1.00) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL8080046 0.92 PPM1B (0.84) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL18235530 0.84 PPM1B (0.72) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL3497096 0.83 TFPI2 (0.74) PPM1BPTPN1PPP1CCTFPI2LMNA
SCHEMBL3191742 0.83 TFPI2 (0.74) PPM1BPTPN1PPP1CCTFPI2LMNA
Endothall SCHEMBL13480837 0.82 TFPI2 (1.00) PPM1BPTPN1PPP1CCTFPI2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348363-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-11-02 US disclosed
US-20230341777-A1 RESIST UNDERLAYER FILM-FORMING COMPOSITION CONTAINING TERMINAL-BLOCKED REACTION PRODUCT NISSAN CHEMICAL CORPORATION (JP) 2023-10-26 US disclosed
US-20230296984-A1 EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2023-09-21 US disclosed
US-20230259028-A1 RESIST UNDERLAYER FILM-FORMING COMPOSITION CONTAINING REACTION PRODUCT OF HYDANTOIN COMPOUNDS NISSAN CHEMICAL CORPORATION (JP) 2023-08-17 US disclosed
US-11236102-B2 Oxabicycloheptane prodrugs LIXTE BIOTECHNOLOGY, INC. (US) 2022-02-01 US disclosed
EP-3736275-A1 OXABICYCLOHEPTANE PRODRUGS FOR USE IN TREATING CANCER Lixte Biotechnology, Inc. (US) 2020-11-11 EP disclosed
US-20200325151-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. 2020-10-15 US disclosed
US-10668062-B2 Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes LIXTE BIOTECHNOLOGY, INC. (US) 2020-06-02 US disclosed
US-10668062-B2 Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes LIXTE BIOTECHNOLOGY, INC. (US) 2020-06-02 US disclosed
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2019-09-03 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
EP-2124550-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE Lixte Biotechnology Holdings, Inc. (US) 2009-12-02 EP disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
WO-2008097561-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) 2008-08-14 WO disclosed
EP-0470469-B1 2-Oxa-3-alkoxy-7-hydroxy-bicyclo[2.2.1]heptanes BASF AG (DE) 1996-03-13 EP disclosed
EP-0226346-B1 BICYCLIC SULFONAMIDE DERIVATIVES SHIONOGI & CO., LTD. (JP) 1991-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC PPM1B 3573/4885PTPN1 3699/4885PPP1CC 3030/4885
US-20230348363-A1 COMPOUNDS AND THEIR USE RXFP1, RXFP3, RXFP2 PPM1B 3811/4885PTPN1 991/4885PPP1CC 4600/4885
US-20200325151-A1 OXABICYCLOHEPTANE PRODRUGS UGT2B7, UGT1A6, UGT1A1 PPM1B 1437/4885PTPN1 1462/4885PPP1CC 1998/4885
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use HCCS, VHL, OXA1L PPM1B 3454/4885PTPN1 3848/4885PPP1CC 3100/4885
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC PPM1B 3573/4885PTPN1 3699/4885PPP1CC 3030/4885
US-10668062-B2 Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes PPP2CA, PPP3CA, PPP6C PPM1B 23/4885PTPN1 76/4885PPP1CC 51/4885
US-11236102-B2 Oxabicycloheptane prodrugs UGT2B7, UGT1A6, UGT1A1 PPM1B 1437/4885PTPN1 1462/4885PPP1CC 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.